SANTA CLARA, Calif.--(BUSINESS WIRE)--
Affymetrix (Nasdaq:AFFX) and BioDiscovery, Inc. today announced the
launch of a new analysis software, Nexus Copy Number for Affymetrix,
which is specifically for data generated by Affymetrix' genetic analysis
platforms in cancer research, including CytoScan®
Cytogenetics Suite and OncoScan®
FFPE Assay Kit.
"CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit are key parts
of our cancer portfolio," says Dr. Andy Last, Executive Vice President
and Chief Operating Officer at Affymetrix. "Researchers have been
finding CNVs and copy neutral changes in liquid and solid tumor samples.
With the use of Nexus
Copy Number, an advanced discovery tool for interrogating large data
sets, researchers have been able to identify biomarkers that drive
disease progression. The new Nexus
Copy Number for Affymetrix software offers researchers a version of
the Nexus Copy Number software that is easier to access and has been
specifically tailored for Affymetrix' assays."
"We are thrilled to extend our relationship with Affymetrix through this
unique product," said Dr. Soheil Shams, BioDiscovery's Chief Scientific
Officer. "The high quality data from the Affymetrix assays performs
extremely well in our software for detecting copy number variants. We
have customers around the world that have been leveraging the CytoScan
Cytogenetics Suite and OncoScan platforms for copy number analysis from
different types of cancer samples, and we're pleased to be able to offer
this joint solution to help scientists to gain further insights into
For product and ordering information on the new Nexus Copy Number for
Affymetrix software, contact BioDiscovery, Inc.
Affymetrix, the Affymetrix logo, OncoScan, and CytoScan are trademarks
of Affymetrix, Inc. All other trademarks and product names are the
property of their respective owners.
Affymetrix and BioDiscovery products mentioned in this release are For
Research Use Only. Not for use in diagnostic procedures.
About BioDiscovery, Inc.
BioDiscovery Nexus Copy Number software offers simple yet powerful tools
for copy number (CNV) and sequence variation analysis and visualization
from microarrays and next generation sequencing (NGS), for analysis of
complex data such as solid tumor samples and complex constitutional
disease. The scientist-driven software embeds powerful statistical tools
designed specifically for the end-user, allowing rapid detection of
chromosomal aberrations and identification of affected pathways.
BioDiscovery is a leader in the development of breakthrough software and
services for advanced copy number variation and expression analysis,
enabling customers in drug discovery, research, and diagnostics by
efficiently managing, integrating, and analyzing data generated using
high-throughput microarray and next-generation sequencing technologies.
For more information about BioDiscovery, please visit www.biodiscovery.com.
Affymetrix technologies enable multiplex and simultaneous analysis of
biological systems at the cell, protein, and gene level, facilitating
the rapid translation of bench-top research into clinical and routine
use for human health and wellness. The Company provides leadership and
support, partnering with customers in pharmaceutical, diagnostic, and
biotechnology companies, as well as leading academic, government, and
non-profit research institutes in their quest to use biology for a
better world. More than 2,300 microarray systems have been shipped
around the world and more than 65,000 peer-reviewed papers have been
published citing Affymetrix technologies. Affymetrix is headquartered in
Santa Clara, California, and has manufacturing facilities in Cleveland,
Ohio, San Diego, Vienna, and Singapore. The Company has about 1,100
employees worldwide and maintains sales and distribution operations
across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix' "expectations," "beliefs," "hopes," "intentions,"
"strategies," or the like. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially for
Affymetrix from those projected. These and other risk factors are
discussed in Affymetrix' Form 10-K for the year ended December 31, 2013,
and other SEC reports for subsequent quarterly periods.
Source: Affymetrix, Inc.